Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre, open-label, phase 1/2 trial Link logo PDF logo

Antonia, Scott J.; Lopez-Martin, Jose A.; Bendell, Johanna; Ott, Patrick A.; Taylor, Matthew; Eder, Joseph Paul; Jaeger, Dirk; Pietanza, M. Catherine; Le, Dung T.; de Braud, Filippo; Morse, Michael A.; Ascierto, Paolo A.; Horn, Leora; Amin, Asim; Pillai, Rathi N.; Evans, Jeffry; Chau, Ian; Bono, Petri; Atmaca, Akin; Sharma, Padmanee

Lancet Oncology Volume 17, Issue 7, Pages 883–895, DOI: 10.1016/S1470-2045(16)30098-5

  • 48 tweets
  • 17 news
  • 137 Mendeley readers

Timeline


Generating chart...


Tweet geographics

By country: 31

Unknown: 17

Generating map...

Tweets

Tweets: 18

Retweets: 30

      Site data sourced from Altmetric.com and CSC (VIRTA)